Letrozole
Endocrine System Diseases
Assiut UniversitySmall moleculePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Endocrine System Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hcg Merck KGaA, Darmstadt, Germany | Phase 3 | BB |
Irinotecan Xiaoxiang Chen | Phase 2 | BB |
Metformin Assiut University | Phase 2 | B |
USISTAPIDE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | B |
GSK-2256294A Vanderbilt University Medical Center | Phase 2 | B |
View all 22 →
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →